Impact of Iso-Osmolar Versus Low-Osmolar Contrast Agents on Contrast-Induced Nephropathy and Tissue Reperfusion in Unselected Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (From the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial)




Conflicting data have been reported on the effects of low-osmolar and iso-osmolar contrast media on contrast-induced acute kidney injury (CI-AKI). In particular, no clinical trial has yet focused on the effect of contemporary contrast media on CI-AKI, epicardial flow, and microcirculatory function in patients with ST-segment elevation acute myocardial infarction who undergo primary percutaneous coronary intervention. The Contrast Media and Nephrotoxicity Following Coronary Revascularization by Angioplasty for Acute Myocardial Infarction (CONTRAST-AMI) trial is a prospective, randomized, single-blind, parallel-group, noninferiority study aiming to evaluate the effects of the low-osmolar contrast medium iopromide compared to the iso-osmolar agent iodixanol on CI-AKI and tissue-level perfusion in patients with ST-segment elevation acute myocardial infarction. Four hundred seventy-five consecutive, unselected patients who underwent primary percutaneous coronary intervention were randomized to iopromide (n = 239) or iodixanol (n = 236). All patients received high-dose N-acetylcysteine and hydration. The primary end point was the proportion of patients with serum creatinine (sCr) increases ≥25% from baseline to 72 hours. Secondary end points were Thrombolysis In Myocardial Infarction (TIMI) myocardial perfusion grade, increase in sCr ≥50%, increase in sCr ≥0.5 or ≥1 mg/dl, and 1-month major adverse cardiac events. The primary end point occurred in 10% of the iopromide group and in 13% of the iodixanol group (95% confidence interval −9% to 3%, p for noninferiority = 0.0002). A TIMI myocardial perfusion grade of 0 or 1 was present in 14% of patients in the 2 groups. No differences between the 2 groups were found in any of the secondary analyses of sCr increase. No significant difference in 1-month major adverse cardiac events was found (8% vs 6%, p = 0.37). In conclusion, in a population of unselected patients with ST-segment elevation acute myocardial infarction who underwent primary percutaneous coronary intervention, iopromide was not inferior to iodixanol in the occurrence of CI-AKI; no significant differences were found in terms of tissue-level reperfusion and major adverse cardiac events between the 2 contrast agents.


Patients with ST-segment elevation acute myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) are at increased risk for contrast-induced acute kidney injury (CI-AKI). In this setting, the choice of contrast medium may influence the risk for CI-AKI. Different responses in coronary hemodynamics and microcirculatory function have been shown after the administration of ionic versus nonionic or low-osmolar contrast media versus high-osmolar contrast media in animal models. In mixed study populations, the use of high-osmolar contrast media has been shown to result in more CI-AKI than the more contemporary low-osmolar contrast media or the iso-osmolar contrast medium iodixanol. Early studies suggested that iso-osmolar agents also reduced the risk for CI-AKI compared to some types of low-osmolar contrast media. However, more recent studies and meta-analyses have shown no difference in CI-AKI when iodixanol was compared to different types of low-osmolar contrast media, even if wide variations exist in relative renal safety by specific low-osmolar contrast media. No clinical trial has yet focused on the effect of contemporary contrast media on CI-AKI in patients with STEMI who undergo PCI. We therefore conducted a randomized controlled trial to verify the noninferiority of the low-osmolar contrast medium iopromide (Ultravist 370; Bayer Schering Pharma AG, Berlin, Germany) to the iso-osmolar contrast medium iodixanol (Visipaque 320; GE Healthcare AS, Oslo, Norway) in terms of nephrotoxic effects and tissue-level perfusion in consecutive, unselected patients with STEMI who underwent PCI.


Methods


The Contrast Media and Nephrotoxicity Following Coronary Revascularization by Angioplasty for Acute Myocardial Infarction (CONTRAST-AMI) study was a prospective, multicenter, randomized, single-blind, parallel-group, noninferiority comparison of the incidence of CI-AKI and optimal tissue-level perfusion between iodixanol and iopromide in patients with STEMI who underwent primary PCI. The study was approved by the institutional ethics committees of each participating center and performed according to Good Clinical Practice standards and the principles of the Declaration of Helsinki and its subsequent amendments. Written informed consent was provided by all patients before enrollment in the study.


From January 2009 to April 2010, all consecutive patients admitted to the participating centers for STEMI who underwent primary PCI <12 hours (18 hours in case of cardiogenic shock) after the onset of symptoms were considered eligible. No upper age limit was used. Criteria for exclusion were pregnancy, lactation, administration of any investigational drug within the previous 30 days, intra-arterial or intravenous administration of iodinated contrast media from 7 days before to 72 hours after the administration of the study agents, intake of nephrotoxic medications from 24 hours before to 24 hours after the administration of the study agents, previous participation in this study, and inability to give informed consent to participate in the study.


Patients were randomized to receive iodixanol or iopromide as part of their catheterization procedures according to a computer-generated balanced randomization scheme that was provided to the study centers. Study agent was administered by intracoronary injection as necessary for each patient, and the total contrast medium volume administered was recorded. Because N-acetylcysteine may prevent CI-AKI with a dose-dependent effect in patients treated with primary PCI, improving hospital outcomes, it was used in all patients (1,200 mg intravenous diluted with 100 ml 5% glucose during the procedure and 1,200 mg orally twice daily for the next 48 hours after PCI). Immediately after intervention, all patients underwent hydration with intravenous isotonic saline (0.9%) at a rate of 1 ml/kg/hour for 12 hours (or 0.5 ml/kg/hour for 12 hours in cases of overt heart failure).


The decision to use intra-aortic balloon pumps, inotropic drugs, abciximab, β blockers, angiotensin-converting enzyme inhibitors, and diuretics was left to the discretion of interventional and coronary care unit cardiologists, as directed by international guidelines. Angiographic markers of epicardial flow and tissue-level perfusion were assessed on completion of diagnostic coronary angiography and shortly after PCI. Left ventricular function was evaluated by echocardiography in all patients <24 hours after admission and at discharge. Investigators reading angiograms and echocardiograms were blinded to the contrast medium randomization. All groups and individuals associated with the study remained blinded until the database was locked and the data analyzed.


Serum creatinine (sCr) was measured at baseline; on days 1, 2, and 3; and at discharge. Creatinine clearance was calculated by applying the Cockcroft-Gault formula to the sCr value.


Coronary angiography and PCI were performed according to standard clinical practice. Patients in the emergency department received a bolus of 5,000 U of unfractionated heparin, followed by additional intraprocedural boluses to maintain an activated clotting time of 200 to 250 seconds (≥300 seconds when abciximab was not used), a bolus of acetylsalicylic acid (500 mg intravenously or 300 mg orally), and an oral clopidogrel loading dose of 300 mg (600 mg if abciximab was not administered). The use of glycoprotein IIb/IIIa inhibitors as well as bare-metal or drug-eluting stents was left to the discretion of the interventionalist. Additional use of thrombectomy was recommended depending on thrombus in the infarct-related artery. All coronary angiograms were evaluated by 2 experienced readers who were unaware of the clinical status and type of the contrast medium used. Flow in the epicardial arteries was assessed before and after coronary intervention for Thrombolysis In Myocardial Infarction (TIMI) flow grade and corrected TIMI frame count by use of previously described methods. The TIMI myocardial perfusion grade (TMPG) was used to assess myocardial tissue-level perfusion. A “closed” microvasculature is defined as TMPG 0 or 1, with TMPG 2 or 3 representative of an “open” microvasculature. TMPG was assessed only in the area supplied by the culprit vessel.


The primary end point was defined as the proportion of patients with relative increases in sCr ≥25% from baseline to 72 hours after study agent administration. The main secondary end point was the proportion of patients with TMPG 2 or 3 in the area supplied by the culprit vessel. Other secondary end points were a relative increase in sCr ≥50%; an absolute increase in sCr ≥0.5 or ≥1 mg/dl; the proportion of patients who required specific treatment for acute renal failure, who required dialysis, or who died of acute renal failure at 1 month; and the proportion of patients with major adverse cardiac events, defined as cardiac death, reinfarction, and rehospitalization for heart failure, at 1 month.


Data are expressed as mean ± SD for continuous variables and as absolute and relative frequencies for categorical variables. Continuous variables were compared between the 2 groups of patients using Student’s 2-sample t tests or Mann-Whitney U tests and categorical variables using chi-square tests or Fisher’s exact tests as appropriate. The primary end point was the comparison of the proportions of patients with sCr increases ≥25% from baseline to 72 hours after contrast agent application (CI-AKI). Iopromide was concluded to be not inferior to iodixanol if the upper limit of the 95% confidence interval for the difference in proportions with CI-AKI was <8% (prespecified noninferiority margin). In a second step, superiority was tested if noninferiority was shown. Superiority was concluded if the upper limit of the 95% confidence interval was <0%. This approach was repeated for all time points (24 hours, 48 hours, and maximum sCr). In addition, logistic regression analysis was applied to model CI-AKI at 72 hours, including the following risk factors: treatment group, age, gender, baseline sCr, volume of contrast agent, and the left ventricular ejection fraction at baseline and at discharge. Backward selection with the criterion of a 2-sided p value <0.05 was used to select the final model. Receiver-operating characteristic curve analysis was performed for significant factors to evaluate accuracy. Comparisons of creatinine levels and relative and absolute changes from baseline between the treatment groups were performed with baseline as the covariate. In case of unbalanced numbers of patients between the treatment groups with missing data for the primary end point, sensitivity analyses were conducted.


The main objective of this study was to evaluate whether the low-osmolar contrast medium is at least not inferior, or even superior, to the iso-osmolar contrast medium with regard to the prevention of CI-AKI. Given the lack of clear superiority of either agent in terms of the prevention of CI-AKI in previous studies, a 2-step design was chosen for the study. In the first step, noninferiority was tested, and in the second step, the superiority of the low-osmolar contrast medium to the iso-osmolar contrast medium was assessed. On the basis of International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines, the noninferiority margin aimed to be less than the largest clinically acceptable difference against the comparator and to preserve the effect of the comparator against a putative placebo comparison. To estimate the power and noninferiority margin at the time of study inception, data from the most pertinent related study was used. An 8% rate of CI-AKI was projected in the group receiving the iso-osmolar contrast medium. With a Δ value (or upper limit of the accepted difference) of 8%, the CI-AKI rate would be clinically relevant, if the iso-osmolar contrast medium group showed a rate of 8% and the low-osmolar contrast medium group a rate of <16%. This is still much better than CI-AKI rate without the use of N-acetylcysteine (33%) and not worse than low-osmolar contrast media with single-dose N-acetylcysteine, as shown by Marenzi et al (15%); moreover, the selected margin is lower compared to the variation observed in previous studies between high- and low-osmolar contrast media.


The sample size was thus based on the assumption of an 8% incidence of CI-AKI in the 2 treatment groups and a noninferiority margin of 8% for the difference in proportions between iopromide and iodixanol. With a level of significance of 0.025 (1 sided), enrollment of a total of 423 patients, accounting for a 5% dropout rate, was planned. The primary end point was tested at a 1-sided level of significance of 0.025, whereas all other statistical tests were 2 sided at a level of significance of 0.05. Statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, North Carolina), and sample size estimation was performed with PASS 2005 (NCSS, Kaysville, Utah).

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Dec 15, 2016 | Posted by in CARDIOLOGY | Comments Off on Impact of Iso-Osmolar Versus Low-Osmolar Contrast Agents on Contrast-Induced Nephropathy and Tissue Reperfusion in Unselected Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (From the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial)

Full access? Get Clinical Tree

Get Clinical Tree app for offline access